PAMVAC-VLP is under clinical development by AdaptVac and currently in Phase I for Malaria. According to GlobalData, Phase I drugs for Malaria have a 70% phase transition success rate (PTSR) indication benchmark for progressing into Phase II. GlobalData’s report assesses how PAMVAC-VLP’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.
Smarter leaders trust GlobalData
GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.
PAMVAC-VLP overview
Vaccine is under investigation for the prevention of pregnancy-associated malaria caused by Plasmodium falciparum. The vaccine candidate constitutes polypeptides corresponding to N-terminal portion of the VAR2CSA proteins. The interaction of this antigen with chondroitin sulfate A (CS-A) is the leading cause for placental malaria.
AdaptVac overview
AdaptVac is a pharmaceutical company which is engaged in developing therapeutic and prophylactic vaccines to detect cancer and immunological disorders.
For a complete picture of PAMVAC-VLP’s drug-specific PTSR and LoA scores, buy the report here.
Data Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.
GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.
GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in clinical development (PTSR), as well as how likely the drug will be approved (LoA). This is based on a combination of machine learning and a proprietary algorithm to process data points from various databases found on GlobalData’s Pharmaceutical Intelligence Center.
